{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039783","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.912666+00:00","generated_at":"2026-06-12T01:30:05.736214+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics Q2 2023: cash $385M, FT522 Phase 1 start-up, FT825 IND planned 2H23","bullets":["Cash position $385.2M as of June 30, 2023; runway into 2H25.","Q2 2023 revenue $0.9M from ONO collaboration; GAAP op ex $63.5M incl $12.9M stock comp.","Phase 1 start-up for FT522 ADR-armed CAR NK program; IND allowed May 2023.","IND submission planned 2H23 for FT825/ONO-8250 HER2-targeted CAR T program under ONO collaboration.","FT576 BCMA-targeted CAR NK and FT819 CD19-targeted CAR T programs enrolling patients in dose escalation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039783","json":"https://secwatch.observer/filing/0000950170-23-039783.json","markdown":"https://secwatch.observer/filing/0000950170-23-039783.md","text":"https://secwatch.observer/filing/0000950170-23-039783.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023039783/0000950170-23-039783-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023039783/fate-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:30:05.736214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0c1b8432f10250d5bc189fd0e84b3c96aa72aa1","claim":"FATE THERAPEUTICS INC reported second quarter ended June 30, 2023 results: revenue $0.9 million.","evidence_excerpt":"June 30, 2023 were $385.2 million. In addition, as of June 30, 2023, cash receivables from the Company’s collaboration with ONO were $2.8 million. • Total Revenue: Revenue was $0.9 million for the second quarter of 2023, which was derived from the Company’s conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023039783/0000950170-23-039783-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$0.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}